Complement System

The discovery of the complement system arose from a fundamental puzzle in late-nineteenth-century microbiology: serum from immunized animals could kill bacteria, yet heating the serum to 56 °C abolished this bactericidal activity while preserving the antibodies within it. This observation implied that a heat-labile factor in blood was required to complement the action of antibodies—hence the name. Understanding this system has since become central to immunology because complement sits at the intersection of innate defense and adaptive immunity, providing rapid, enzymatic amplification of antimicrobial responses long before adaptive effectors reach full strength.

The central question that drove over a century of complement research was deceptively simple: how does the host generate a rapid, broadly effective antimicrobial response in the blood and tissues before the adaptive immune system mounts a specific reply? The answer—a tightly regulated cascade of more than 30 soluble and membrane-bound proteins—turns out to be one of the most elegant enzymatic amplification systems in biology. As we will explore, complement not only lyses pathogens directly but also opsonizes targets for phagocytosis, recruits inflammatory cells, and modulates adaptive immune responses.

The complement system operates through a set of fundamental principles that govern its activation, amplification, and regulation. At its core, complement is a proteolytic cascade: inactive precursor proteins (zymogens) circulate in the blood and are sequentially cleaved to generate active enzymes and bioactive fragments. Each activated component catalyzes the cleavage of many molecules of the next component, creating exponential amplification. Because this amplification is powerful enough to damage host cells, a parallel system of regulatory proteins ensures that complement activity remains focused on foreign surfaces and is rapidly attenuated on self tissue.

The diagram above captures the organizational logic of the complement system. Notice that the classical and lectin pathways generate identical C3 convertases (C4b2a), whereas the alternative pathway produces a structurally distinct convertase (C3bBb). Despite this difference, both convertases perform the same catalytic function: they cleave C3 into C3a and C3b. This convergence at C3 is what allows a single downstream cascade—assembly of the C5 convertase and ultimately the membrane attack complex—to serve all three pathways. The alternative pathway also functions as a built-in amplification loop: newly deposited C3b molecules recruit Factor B and Factor D to form additional C3bBb convertases, creating a positive feedback cycle that rapidly coats pathogen surfaces.

Classical Pathway

The classical pathway is initiated when the C1 complex binds to antigen–antibody complexes. The C1 complex consists of one molecule of C1q associated with two molecules each of C1r and C1s (written C1q:C1r₂:C1s₂). C1q has six globular heads that recognize the Fc regions of IgG or IgM bound to antigen; at least two heads must be engaged for stable binding, which explains why pentameric IgM is far more efficient than IgG at activating this pathway. Binding triggers autoactivation of C1r, which then cleaves C1s to generate an active serine protease. Activated C1s cleaves C4 into C4a (a weak anaphylatoxin) and C4b, which covalently binds to the target surface via a thioester bond. C4b then recruits C2, which is cleaved by C1s into C2a (the catalytic subunit) and C2b, forming the classical C3 convertase C4b2a.

Lectin Pathway

The lectin pathway bypasses the need for antibodies altogether. It is initiated when mannose-binding lectin (MBL) or ficolins recognize conserved carbohydrate patterns—particularly terminal mannose, fucose, or N-acetylglucosamine residues—on microbial surfaces. MBL is structurally similar to C1q and associates with MBL-associated serine proteases (MASP-1 and MASP-2), which are functional homologs of C1r and C1s. Upon binding, MASP-2 cleaves C4 and C2 in exactly the same manner as activated C1s, generating the same C4b2a C3 convertase. Because microbial glycans differ systematically from mammalian glycans (which are typically capped with sialic acid), the lectin pathway provides pattern-based discrimination between self and non-self.

Alternative Pathway

The alternative pathway is unique in that it is constitutively active at a low level through a process called tick-over. In plasma, the thioester bond within native C3 undergoes spontaneous hydrolysis at a slow but constant rate, generating C3(H₂O), a conformationally altered form of C3 that can bind Factor B. Factor B in this complex is then cleaved by the serine protease Factor D into Ba (released) and Bb (retained), forming a fluid-phase C3 convertase C3(H₂O)Bb. This enzyme cleaves additional C3 to produce C3b, which can attach covalently to any nearby surface. On host cell surfaces, regulatory proteins (Factor H, MCP/CD46, DAF/CD55) rapidly inactivate deposited C3b. On microbial surfaces that lack these regulators, C3b associates with Factor B and Factor D to form the surface-bound alternative pathway C3 convertase C3bBb, which is stabilized by properdin (Factor P). This creates a powerful amplification loop.

Terminal Pathway: The Membrane Attack Complex

When a C3 convertase (either C4b2a or C3bBb) binds an additional C3b molecule, it becomes a C5 convertase (C4b2a3b or C3bBb3b). This enzyme cleaves C5 into C5a (the most potent anaphylatoxin) and C5b. C5b initiates assembly of the membrane attack complex (MAC). C5b sequentially binds C6, C7, and C8; the C5b-8 complex then recruits 10–16 molecules of C9, which polymerize to form a transmembrane pore approximately 10 nm in diameter. This pore disrupts the osmotic integrity of the target cell, leading to lysis. The MAC is particularly effective against Gram-negative bacteria, whose outer membrane is susceptible to pore formation, whereas Gram-positive bacteria are generally resistant due to their thick peptidoglycan layer.

A particularly important bridge between innate and adaptive immunity is the role of C3d. When C3b on an antigen surface is successively degraded to iC3b and then to C3d, the C3d fragment remains covalently attached. When a B cell encounters this antigen, C3d simultaneously engages CR2 (CD21) in the B-cell co-receptor complex (CD19/CD21/CD81). This co-stimulatory signal lowers the threshold for B-cell activation by up to 1,000-fold, illustrating how complement directly modulates adaptive immune responses.

Consider the following scenario: a patient with a confirmed Neisseria meningitidis (Gram-negative) bloodstream infection has IgM antibodies against the bacterial capsular polysaccharide. Trace the complement cascade from initiation to pathogen destruction and predict the effector outcomes.

The clinical importance of complement is most dramatically illustrated by complement deficiency syndromes. These genetic conditions reveal the non-redundant roles of specific complement components and have driven the development of complement-targeted therapies. The table below correlates deficiency with clinical phenotype, providing a framework for understanding how loss of specific complement functions translates to disease susceptibility.

Beyond genetic deficiencies, complement dysregulation is implicated in a growing list of conditions including age-related macular degeneration (Factor H polymorphisms), transplant rejection (antibody-mediated complement activation on graft endothelium), and even neurodegenerative diseases where complement-mediated synaptic pruning goes awry. As our understanding of complement biology deepens, the system has transitioned from a textbook curiosity to a major therapeutic target in modern medicine.